WO2019093340A1 - Procédé d'induction d'endoderme primitif à partir de cellules souches pluripotentes naïves - Google Patents

Procédé d'induction d'endoderme primitif à partir de cellules souches pluripotentes naïves Download PDF

Info

Publication number
WO2019093340A1
WO2019093340A1 PCT/JP2018/041243 JP2018041243W WO2019093340A1 WO 2019093340 A1 WO2019093340 A1 WO 2019093340A1 JP 2018041243 W JP2018041243 W JP 2018041243W WO 2019093340 A1 WO2019093340 A1 WO 2019093340A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
primitive endoderm
pluripotent stem
stem cells
naive
Prior art date
Application number
PCT/JP2018/041243
Other languages
English (en)
Japanese (ja)
Inventor
康弘 ▲高▼島
巧 大久保
克憲 蝉
Original Assignee
国立大学法人京都大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人京都大学 filed Critical 国立大学法人京都大学
Priority to JP2019552818A priority Critical patent/JP7176764B2/ja
Publication of WO2019093340A1 publication Critical patent/WO2019093340A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor

Definitions

  • the present invention relates to a method of primordial endoderm induction from naive pluripotent stem cells.
  • the present invention also relates to a medium suitably used to derive primitive endoderm from naive type pluripotent stem cells.
  • the present invention also relates to molecular markers for efficiently detecting and separating primitive endoderm.
  • the invention further relates to methods of mimicking gastrulation by co-culture of primitive endoderm and epiblast and inducing mesendoderm differentiation.
  • Takashima who is one of the present inventors, is a naive type pluripotent that resets human pluripotent stem cells to the same state as the basal state by expressing two genes of NANOG and KLF2 in human pluripotent stem cells.
  • We have succeeded in obtaining sexual stem cells (Non-patent Document 1), and use this to analyze the induction and early development of primitive endoderm (Non-patent document 2).
  • the present inventors diligently studied to solve the above problems. As a result, it was found that primitive endoderm can be efficiently induced by culturing naive pluripotent stem cells in a medium containing BMP (Bone morphogenetic protein) and FGF4 (Fibroblast growth factor 4). Furthermore, it was found that co-culture of the obtained primitive endoderm with primed pluripotent stem cells mimics gastrulation to induce mesendoderm differentiation. Furthermore, the present invention was completed based on the finding that CEACAM1 (carcinoembrytic antigen related cell adhesion molecule 1) and ANPEP (alanyl aminopeptidase, membrane) can be efficiently used for selection and detection of primitive endoderm as a specific marker of primitive endoderm. .
  • BMP Breast morphogenetic protein
  • FGF4 Fibroblast growth factor 4
  • the present invention provides the following.
  • [1] A method for preparing primitive endoderm in vitro from pluripotent stem cells, Culturing naive pluripotent stem cells in a medium containing BMP and FGF4 to induce primitive endoderm differentiation.
  • the medium further contains one or more selected from PDGF (Platelet-Derived Growth Factor), IL-6 (Interleukine 6), TGF (Transforming Growth Factor) ⁇ inhibitor, Wnt signal inhibitor and retinoic acid
  • PDGF Platinum-Derived Growth Factor
  • IL-6 Interleukine 6
  • TGF Transforming Growth Factor
  • Wnt signal inhibitor and retinoic acid
  • the method of preparing primitive endoderm according to [1] which comprises.
  • [3] The method for preparing primitive endoderm described in [1], wherein the medium comprises BMP, FGF4, a TGF ⁇ inhibitor and a Wnt signal inhibitor.
  • [7] The method of preparing primitive endoderm according to any of [1] to [6], wherein the pluripotent stem cells are human pluripotent stem cells.
  • a step of preparing primitive endoderm by the method according to any of [8] [1] to [7], and copriming the obtained primitive endoderm with primed pluripotent stem cells for primed pluripotency A method for preparing mesendoderm, comprising the step of differentiating an adult stem cell to mesendoderm.
  • a myocardium including the steps of preparing mesendoderm by the method described in [9] [8], and further culturing the obtained mesendoderm to differentiate it into myocardial progenitor cells and / or pancreatic progenitor cells.
  • Method of preparing precursor cells and / or pancreatic precursor cells [10] Providing primitive endoderm, and co-culturing the primitive endoderm with primed pluripotent stem cells to differentiate primed pluripotent stem cells to mesoderm. Method of preparation. [11] Primitive endoderm cells prepared by the method according to any one of [1] to [7]. [12] A method for separating primitive endoderm cells from a cell population containing primitive endoderm cells, comprising the step of selecting primitive endoderm cells using CEACAM1 or ANPEP. [13] A method for detecting primitive endoderm cells in a cell population containing primitive endoderm cells, comprising the step of detecting primitive endoderm cells using CEACAM1 or ANPEP.
  • a reagent for detecting primitive endoderm cells which comprises a molecule that specifically binds to CEACAM1 or ANPEP.
  • a medium for naive type pluripotent stem cells comprising BMP and FGF4.
  • the medium for naive type pluripotent stem cells according to [15] which comprises BMP, FGF4, a TGF ⁇ inhibitor and a Wnt signal inhibitor.
  • primitive endoderm can be easily derived from pluripotent stem cells simply by culture procedures without forced expression of a gene. Furthermore, co-culture of primordial endoderm with primed pluripotent stem cells can mimic gastrulation in physiological developmental processes to achieve mesendoderm differentiation, and furthermore, from mesendoderm Differentiation can be induced to myocardial progenitor cells and pancreatic progenitor cells.
  • the method of the present invention realizes differentiation induction to primitive endoderm, which is an extraembryonic cell which is difficult in conventional prime type pluripotent stem cells, by a simple procedure, and is functionally functional using pluripotent stem cells. It is an innovative method that can be a basic technology to derive mature cells and tissues.
  • the method of the present invention is useful for elucidation of developmental mechanism, regenerative medicine, elucidation of the mechanism of disease at the developmental stage, treatment and the like.
  • the method for sorting / detecting primitive endoderm using the molecular marker of the present invention is useful because it can selectively sort / detect primitive endoderm cells.
  • FIG. 2 shows the procedure for inducing expression of GATA gene or SOX gene in pluripotent stem cells (PSC).
  • PSC pluripotent stem cells
  • the naive type PSC which overexpressed GATA6 gene or GATA4 gene it divided into a PDGFRA positive cell and a PDGFRA negative cell, and the graph which showed the time-dependent change of the expression level of the endogenous gene in each.
  • SFO3 non-serum medium
  • GMEM serum medium
  • the figure which shows the result of having analyzed the expression level of a primitive streak related gene or an endoderm related gene in PDGFRA positive cells (Day1, Day 3) induced by overexpressing GATA6 in naive type PSC or primed PSC (N 2).
  • the results of Day 0 are also shown.
  • the results of comparison of the expression of Top100 gene for Epiblast and primitive endoderm (PrE) in human embryos in cells (H0-naive-GATA6) (Day 0, Day 1 and Day 3) induced by expressing GATA6 in naive PSC are shown.
  • Results of ChIP-seq (GATA6, GATA4, SOX17, HNF4A or PDGFRA) in cells (H9-naive-GATA6 and H9-primed-GATA6) induced by expressing GATA6 in naive PSC or primed PSC Figure showing.
  • the results of Day 0 are also shown.
  • the results of Day 0 are also shown.
  • FIG. 1 The figure which shows the result of having compared the expression level of CEACAM1 gene in a naive type PSC origin PDGFRA positive cell and a prime type PSC origin PDGFRA positive cell.
  • the expression level of CEACAM1 in naive PSC (before differentiation induction), GATA6 forced expression naive type PSC, 7 factor culture naive type PSC, primed PSC (before differentiation induction) or GATA6 forced expression primed PSC was analyzed by flow cytometry
  • FIG. The figure which shows the result of having analyzed the expression level of ANPEP and CEACAM1 in naive type PSC (before differentiation induction), GATA6 forced expression naive type PSC, and 7 factor culture naive type PSC by flow cytometry.
  • FIG. 1 The expression level (Day 0, Day 3, reculture 13 days) of visceral endoderm gene, yolk sac gene and extraembryonic mesoderm gene in naive PSC-derived PDGFRA positive cells and primed PSC-derived PDGFRA positive cells is compared.
  • Figure. The figure which shows the result of having analyzed the expression of T and OCT3 / 4 by an immunostaining by coculturing a naive type PSC origin PDGFRA positive cell (primitive endoderm cell) and prime type PSC, and analyzing it.
  • the method of preparing primitive endoderm of the present invention from pluripotent stem cells in vitro comprises Naive pluripotent stem cells, BMP (Bone morphogenetic protein) and FGF4 (Fibroblast growth factor 4) Culturing in a medium containing S. and inducing primitive endoderm differentiation.
  • the medium is at least one selected from PDGF, IL-6, a TGF ⁇ inhibitor, a Wnt signal inhibitor and retinoic acid in addition to BMP and FGF4, preferably two or more, more preferably three or more, further preferably Preferably, four or more, particularly preferably all five) are contained.
  • the medium comprises, in addition to BMP and FGF4, a TGF ⁇ inhibitor and a Wnt signal inhibitor.
  • a pluripotent stem cell is a stem cell having pluripotency capable of differentiating into many cells existing in a living body, and also having proliferation ability, any of which can be induced to primitive endoderm. Cells are included.
  • pluripotent stem cells include, but are not limited to, embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, cloned embryonic derived embryonic stem (ntES) cells obtained by nuclear transfer, spermatozoa Stem cells ("GS cells”), embryonic germ cells (“EG cells”), cultured fibroblasts, and pluripotent cells derived from bone marrow stem cells (Muse cells), and the like are included.
  • Preferred pluripotent stem cells are iPS cells and ES cells.
  • the pluripotent stem cell is preferably derived from a mammal, more preferably from a primate, and even more preferably from a human.
  • the reprogramming factor includes, for example, Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15.
  • Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1 and other genes or gene products are exemplified, and these reprogramming factors may be used alone or in combination. Also good.
  • Somatic cells include, but are not limited to, fetal (child) somatic cells, neonatal (child) somatic cells, and any mature healthy or diseased somatic cells, and also primary culture cells. , Passage cells, and cell lines are also included.
  • somatic cells are, for example, (1) tissue stem cells (somatic stem cells) such as neural stem cells, hematopoietic stem cells, mesenchymal stem cells, dental pulp stem cells, (2) tissue precursor cells, (3) blood cells (peripheral Blood cells, cord blood cells etc.), lymphocytes, epithelial cells, endothelial cells, muscle cells, fibroblasts (skin cells etc.), hair cells, hepatocytes, gastric mucous cells, enterocytes, splenocytes, pancreatic cells (pancreatic exocrine cells) Etc.), differentiated cells such as brain cells, lung cells, kidney cells and adipocytes.
  • tissue stem cells such as neural stem cells, hematopoietic stem cells, mesenchy
  • naive type pluripotent stem cells are pluripotent stem cells having properties similar to those of pre-implantation embryo, specifically, they have the following features (Cytometry Research 27 (1): 19 ⁇ 24, 2017). It shows a domed colony morphology, and the colony size is smaller than that of the primed one. One or more of CD75, KLF4 and TFCP2L1 are expressed as markers. The genome is demethylated.
  • Naive pluripotent stem cells can be prepared, for example, by the following method.
  • Method using overexpression of NANOG and KLF2 (Takashima et al., Cell 158: 1254-1269, 2014)
  • Method using 5i LFA condition (Theunissen et al., Cell Stem Cell. 2016 Oct 6; 19 (4): 502-515.)
  • Method using HDAC (histone deacetylase) inhibitor (Guo, G. et al. (2017).
  • Primed pluripotent stem cells are pluripotent stem cells having properties similar to postimplantation embryo epiblasts, they are generally induced pluripotency obtained by introducing a reprogramming factor into somatic cells Stem cells and human ES cells fall under this category and have not been subjected to the above-described naive treatment.
  • Primed pluripotent stem cells have the following features. It shows flat colony morphology and colony size is larger than naive type. As markers, CD75, KLF4 and TFCP2L1 are negative. The genome is methylated.
  • a TGF ⁇ inhibitor is a substance that inhibits signal transduction from binding of TGF ⁇ to the receptor to SMAD, and a substance that inhibits binding to the receptor ALK (activin receptor-like kinase) family, or ALK Substances that inhibit the phosphorylation of SMAD by a family can be mentioned, for example, Lefty-1 (NCBI Accession No.
  • the TGF ⁇ inhibitor used in the present invention is preferably A83-01.
  • the concentration of the TGF ⁇ inhibitor contained in the culture solution can be appropriately selected according to the type of the TGF ⁇ inhibitor.
  • the concentration that exerts the TGF ⁇ inhibitory effect can be appropriately selected according to the type of the TGF ⁇ inhibitor.
  • it is usually 0.025 to It is in the range of 100 ⁇ M, preferably 0.075 to 50 ⁇ M, more preferably 0.25 to 10 ⁇ M.
  • the Wnt signal inhibitor is not particularly limited as long as it can suppress the Wnt signaling pathway involved in gene expression and cytoskeleton regulation, and specifically, XAV939 (tankyrase inhibitor), IWP-1, IWP- 2, low molecular weight compounds such as IWP-3, IWP-4, IWR-1, 53AH (more porcupine inhibitors), KY02111 and derivatives thereof, proteins such as IGFBP4, DKK1, Wnt-C59, Wnt and Wnt signals Antisense nucleic acid, RNA interference inducing nucleic acid (eg, siRNA), competitive peptide, antagonist peptide, inhibitory antibody, antibody-ScFV fragment, dominant negative mutant, and expression vectors for suppressing protein expression or function constituting pathway Low molecular weight Wnt signaling inhibitor preferably compounds, it can be preferably exemplified a XAV939 and IWP-4.
  • the concentration that exerts the Wnt signal inhibitory effect can be appropriately selected according to the type of Wnt signal inhibitor, and, for example, when using XAV 939, it is usually 0.025 to It is in the range of 100 ⁇ M, preferably 0.075 to 50 ⁇ M, more preferably 0.25 to 10 ⁇ M.
  • the PDGF used in step (i) is preferably a protein having a dimer structure, such as dimers with type A monomers (PDGF-AA), dimers with type B monomers (PDGF-BB), A Examples are dimers of type monomers and type B monomers (PDGF-AB) and the like, with preference given to PDGF-AA.
  • PDGF is preferably of mammalian origin, preferably of human origin.
  • human PDGF-A for example, a protein having the amino acid sequence of NCBI (National Center for Biotechnology Information) accession number: NM_002607 can be mentioned.
  • PDGF includes its fragments and functional variants as long as it has the desired differentiation inducing activity.
  • PDGF may be commercially available, or proteins purified from cells or recombinantly produced proteins may be used.
  • concentration of PDGF dimer contained in the culture solution is 0.1 ng / ml to 100 ng / ml, preferably 0.5 ng / ml to 50 ng / ml, more preferably 5 ng / ml to 20 ng / ml.
  • the BMP includes at least one BMP selected from the group consisting of BMP2, BMP4 and BMP6, but is preferably BMP4.
  • the BMP is preferably derived from a mammal, and is preferably derived from a human.
  • the human BMP4 includes, for example, a protein having the amino acid sequence of the accession number: AAH20546.1 of the National Center for Biotechnology Information (NCBI). As long as BMP has a desired differentiation inducing activity, fragments and functional variants thereof are included.
  • BMPs may be commercially available, or proteins purified from cells or recombinantly produced proteins may be used.
  • the concentration of BMP contained in the culture solution is 0.1 ng / ml to 1000 ng / ml, preferably 1 ng / ml to 500 ng / ml, more preferably 10 ng / ml to 200 ng / ml.
  • Retinoic acid may be retinoic acid itself or may be a retinoic acid derivative that retains the differentiation-inducing function of natural retinoic acid.
  • retinoic acid derivatives include 3-dehydroretinoic acid, 4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbonyl] amino] -benzoic acid ( AM 580) (Tamura K, et al., Cell Differ. Dev.
  • retinoic acid or a derivative thereof contained in the culture solution is, for example, 1 nM to 1000 nM, preferably 5 nM to 500 nM, more preferably 10 nM to 250 nM.
  • the FGF4 is preferably derived from a mammal, and is preferably derived from a human.
  • human FGF4 for example, a protein having the amino acid sequence of NCBI (National Center for Biotechnology Information) accession number: NM_002007 can be mentioned.
  • FGF4 has a desired differentiation inducing activity, fragments and functional variants thereof are included.
  • FGF4 a commercially available one may be used, or a protein purified from cells or a recombinantly produced protein may be used.
  • the concentration of FGF4 contained in the culture solution is 0.1 ng / ml to 1000 ng / ml, preferably 1 ng / ml to 500 ng / ml, more preferably 10 ng / ml to 100 ng / ml.
  • IL-6 is preferably of mammalian origin, preferably of human origin.
  • human IL-6 include a protein having the amino acid sequence of accession number: M18403 of National Center for Biotechnology Information (NCBI).
  • NCBI National Center for Biotechnology Information
  • IL-6 has a desired differentiation inducing activity, fragments and functional variants thereof are included.
  • IL-6 a commercially available one may be used, or a protein purified from cells or a recombinantly produced protein may be used.
  • the concentration of IL-6 contained in the culture solution is 0.1 ng / ml to 1000 ng / ml, preferably 1 ng / ml to 500 ng / ml, more preferably 10 ng / ml to 100 ng / ml.
  • the culture solution used in the primitive endoderm induction step is not particularly limited, but it is possible to use BMP and FGF4, preferably further PDGF, IL-6, TGF ⁇ inhibitor, Wnt signal inhibitor and retinoin in naive pluripotent stem cell maintenance medium. It can be prepared by adding one or more types (preferably two or more types, more preferably three types or more, further preferably four types or more, particularly preferably all five types) selected from acids. These factors may be added at different times. For example, IL-6 can also be added 48 hours after initiation of induction. As a naive type pluripotent stem cell maintenance medium, for example, the following medium can be used.
  • the medium may contain serum or serum free may be used.
  • serum for example, albumin, insulin, transferrin, selenium, fatty acid, trace element, 2-mercaptoethanol, thiolglycerol, lipid, amino acid, L-glutamine, non-essential amino acid, vitamin, growth factor, low molecular weight compound, antibiotic It may also contain one or more substances such as substances, antioxidants, pyruvate, buffers, mineral salts, cytokines and the like.
  • naive type pluripotent stem cells may be adherent culture or suspension culture, and in the case of adherent culture, the culture vessel may be coated and used, or coculture with a feeder cell etc. Good.
  • feeder cells to be cocultured include primary fibroblasts (MEF) derived from mouse embryos treated with mitomycin C, STO cells, SNL cells, OP9 cells, C3H10T1 / 2 cells and the like.
  • a culture vessel which has not been artificially treated eg, coated with an extracellular matrix etc.
  • a treatment which artificially suppresses adhesion eg, poly Hydroxyethyl methacrylate (poly-HEMA), nonionic surface-active polyol (Pluronic F-127 etc.) or phospholipid analogue structure (eg, water-soluble polymer having 2-methacryloyloxyethyl phosphorylcholine as a structural unit (Lipidure) It can be carried out by using a culture vessel coated with.
  • the extracellular matrix is a supramolecular structure existing outside the cell, and may be naturally derived or artificial (recombinant).
  • substances such as polylysine, polyornithine, collagen, proteoglycan, fibronectin, hyaluronic acid, tenascin, entactin, elastin, fibrillin, laminin and fragments thereof can be mentioned.
  • These extracellular matrices may be used in combination, for example, preparations from cells such as BD MatrigelTM.
  • the culture temperature conditions for culturing naive type pluripotent stem cells in the primitive endoderm induction step are not particularly limited, and for example, about 37 ° C. to about 42 ° C., about 37 to about 39 ° C. is preferable.
  • the culture period can be appropriately determined by those skilled in the art while monitoring the number of cells and the like.
  • the number of days is not particularly limited as long as primitive endoderm is obtained, and is, for example, at least 1 day or more, preferably 2 to 5 days.
  • Primitive endoderm can be GATA3, GATA4, GATA6, SOX17, FOXA2 (Forkhead Box A2), HNF4A (Hepatocyte Nuclear Factor 4 Alpha), CER1 (Cerberus 1), OTX2 (Orthodenticle Homeobox 2), PDGFRA (Platelet Derived Growth Receptor Receptor) It is characterized by the expression of one or more of primitive endoderm markers such as COL4A1 (alpha-1 subunit of collagen type IV), SPARC (Secreted protein acidic and rich in cysteine) and the like. In addition to these one or more markers, cells expressing CEACAM1 or ANPEP described later are more preferable.
  • COL4A1 alpha-1 subunit of collagen type IV
  • SPARC Secreted protein acidic and rich in cysteine
  • a step of selecting primitive endoderm can be performed after performing a primitive endoderm induction step.
  • the sorted primitive endoderm can be further differentiated into visceral endoderm and yolk sac by continuing the culture. Sorting can be performed using the expression of one or more types of primitive endoderm-specific markers as described above as an indicator.
  • expression of each marker protein may be used as an index, or the gene encoding each of the above marker proteins is expressed (mRNA is expressed) What you do may be an indicator.
  • a reagent used for sorting primitive endoderm cells as in extraction or detection, from a cell population containing primitive endoderm cells, a reagent having a specific affinity to the above-mentioned primitive endoderm marker Anything can be used, and antibodies, aptamers, peptides or compounds that specifically recognize can be used, preferably antibodies or fragments thereof.
  • primers and probes that hybridize to these marker genes can be used.
  • the antibodies may be polyclonal or monoclonal antibodies. These antibodies can be made using techniques well known to those skilled in the art (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Section 11.12-11.13). Specifically, when the antibody of the present invention is a polyclonal antibody, non-human animals such as rabbits are synthesized by synthesizing a marker protein expressed and purified in E. coli according to a conventional method, or an oligopeptide having a partial amino acid sequence. And can be obtained according to a conventional method from the serum of the immunized animal.
  • a monoclonal antibody in the case of a monoclonal antibody, it can be obtained from hybridoma cells prepared by fusing the spleen cells obtained from the above-mentioned immunized non-human animal with myeloma cells (Current protocols in Molecular Biology) Ausubel et al. (1987) Publish. John Wiley and Sons. Section 11.4-11.11).
  • antibody fragments include a portion of an antibody (eg, a Fab fragment) or a synthetic antibody fragment (eg, a single chain Fv fragment “ScFv”). Fragments of antibodies such as Fab and F (ab) 2 fragments can also be produced by methods well known in the art of genetic engineering.
  • the marker is a membrane protein, it is preferably an antibody to the extracellular domain.
  • the antibody may be a commercially available antibody.
  • a reagent such as an antibody having the affinity is, for example, a fluorescent label, a radioactive label, a chemiluminescent label, an enzyme, a detectable substance such as biotin or streptavidin, or protein A, It may be bound or conjugated to a substance that enables isolated extraction such as protein G, beads, magnetic beads and the like.
  • Examples of methods for sorting (as well as extraction or detection) primitive endoderm cells include methods using a flow cytometer.
  • a method of sedimentation using an antibody bound to a carrier a method of sorting cells by magnetism using magnetic beads (for example, MACS), a method of using a cell sorter using a fluorescent label, or immobilization of antibodies etc.
  • the method etc. which use the carrier for example, cell concentration column), etc. are illustrated.
  • CEACAM1 or ANPEP can be suitably used as a marker for naive type pluripotent stem cell-derived primitive endoderm
  • the present invention relates to primitive endoderm cells from a cell population containing primitive endoderm cells.
  • a method of sorting (separating) or detecting, comprising sorting (separating) or detecting primitive endoderm cells using CEACAM1 or ANPEP is provided. Both CEACAM1 and ANPEP may be used.
  • CEACAM1 also called CD66
  • CD66 is a type I transmembrane glycoprotein expressed in epithelial cells, T cells and the like, and is classified as an intercellular adhesion factor.
  • the amino acid sequence registered as P13688 (CEAM1_HUMAN) in UniProt Knowledgebase (UniProtKB) as the amino acid sequence of human CEACAM1 is mentioned.
  • ANPEP also called Aminopeptidase N (APN), CD13, or PEPN
  • ANPEP is a peptidase present in membranes.
  • P15144 AMPN_HUMAN
  • UniProtKB an amino acid sequence of human ANPEP is mentioned.
  • cell population containing primitive endoderm cells is a collection of cells containing primitive endoderm cells, regardless of the origin, although naive pluripotent stem cells ( It is preferable that it is a cell population containing primitive endoderm cells obtained by inducing differentiation of human naive type pluripotent stem cells) to primitive endoderm.
  • the method of differentiation induction from naive type pluripotent stem cells to primitive endoderm is not limited to the above, and may be obtained by a differentiation induction method by gene transfer such as GATA6.
  • sorting (separation) of primitive endoderm cells means to increase the proportion of primitive endoderm cells as compared to that before sorting (separation), preferably 50 primitive endoderm cells. %, 60%, 70%, 80% or 90% or more. More preferably, it is to obtain cells consisting of 100% primitive endoderm cells.
  • primitive endoderm cells When selecting (separating) primitive endoderm cells from a cell population containing primitive endoderm cells using CEACAM1 or ANPEP as an index, it may be used in combination with primitive endoderm markers such as GATA4, GATA6, SOX17, FOXA2 described above, etc. Good. This enhances the enrichment rate of primitive endoderm as compared to using CEACAM1 or ANPEP alone.
  • selectively selecting (separating) cells that are positive for the marker may be selecting (separating) all cells that are positive for the marker, but selecting cells having a certain amount or more of the marker expression amount It may be (separated). For example, in the primitive endoderm-containing cell population, cells expressing the marker within the top 50%, cells within the top 40%, cells within the top 33%, cells within the top 30%, within the top 20% Cells, or cells within the top 10%, can be selectively harvested.
  • the present invention also provides a kit for sorting or detecting primitive endoderm cells, which comprises a reagent that specifically binds to CEACAM1 or ANPEP.
  • the detection reagents contained in the present extraction kit are as described above, and include antibodies against CEACAM1 or ANPEP, and polynucleotides that hybridize to the CEACAM1 gene or ANPEP gene.
  • the extraction kit in the present invention may also contain, together with a reagent that specifically binds to CEACAM1 or ANPEP, instructions describing how to use the detection reagent.
  • the present invention also provides a method for preparing mesendoderm, which comprises co-culturing primitive endoderm with primed pluripotent stem cells to differentiate primed pluripotent stem cells into mesoderm. Furthermore, there is provided a method for preparing cardiac muscle progenitor cells and / or pancreatic progenitor cells, comprising the step of culturing the obtained mesendoderm to differentiate into cultured cardiac progenitor cells and / or pancreatic progenitor cells.
  • the primitive endoderm may be obtained by the method as described above, or may be obtained by other methods such as forced expression of GATA6 gene or the like in naive pluripotent stem cells.
  • epiblasts In ontogeny, epiblasts cause gastrulation and form meso- and endoderm, which differentiate and develop. Primitive endoderm is present in contact with epiblasts and plays an essential role in gastrulation. Therefore, by co-culturing primitive endoderm and primed pluripotent stem cells (iPS cells and ES cells), it is possible to create the state of gastrulation in vitro, which is close to the physiological early implantation stage development. .
  • iPS cells and ES cells primed pluripotent stem cells
  • primed pluripotent stem cells differentiate into mesendoderm as an epiblast, and primitive endoderm differentiates into yolk sac.
  • Mesendoderm can be identified by expression of the marker molecule T (Brachyury).
  • coculture of primitive endoderm and primed pluripotent stem cells can be performed by seeding cultured primitive endoderm cells with primed pluripotent stem cells.
  • the medium is a medium for iPS / ES cells such as AK03, mTeSR1 or F12 / KSR, and may be cultured by adding an extracellular matrix component such as Matrigel.
  • the ratio of the numbers of primitive endoderm and primed pluripotent stem cells to be subjected to co-culture is preferably 1: 3 to 3: 1, more preferably 1: 2 to 2: 1, and particularly preferably 1: 1.
  • the culture temperature conditions for co-cultivation are not particularly limited, but for example, about 37 ° C. to about 42 ° C., about 37 to about 39 ° C. is preferable.
  • the culture period is not particularly limited, and for example, it is at least 12 hours or more, preferably 24 to 48 hours.
  • myocardial progenitor cells and / or pancreatic progenitor cells can be obtained.
  • TGF ⁇ inhibitor BMP, Wnt signal inhibitor, activin and the like
  • KGF keratinocyte growth factor
  • sonic hedge hock inhibitor retinoic acid
  • BMP inhibitor protein kinase C activator (such as phorbol ester) etc.
  • Myocardial progenitor cells can be identified by the expression of the marker molecule Troponin T (TnT). It can also be identified by expression of PDX1, a pancreatic precursor cell marker molecule.
  • the present invention is also directed to a culture medium for naive pluripotent stem cells for inducing differentiation into primitive endoderm including BMP and FGF4, preferably BMP and FGF4 and PDGF, IL-6, TGF ⁇ inhibitor, Wnt signal inhibitor and For induction of differentiation to primitive endoderm comprising one or more types (preferably 2 or more types, more preferably 3 types or more, still more preferably 4 types or more, particularly preferably all 5 types) selected from retinoic acid
  • a medium for naive type pluripotent stem cells for inducing differentiation into primitive endoderm including BMP and FGF4, preferably BMP and FGF4 and PDGF, IL-6, TGF ⁇ inhibitor, Wnt signal inhibitor and For induction of differentiation to primitive endoderm comprising one or more types (preferably 2 or more types, more preferably 3 types or more, still more preferably 4 types or more, particularly preferably all 5 types) selected from retinoic acid
  • a medium for naive type pluripotent stem cells
  • media prepared in advance such that each component is contained at a concentration effective for inducing differentiation into primitive endoderm, or may be prepared and used by adding each component immediately before use. Good.
  • These factors may be added at different times. For example, IL-6 can also be added 48 hours after initiation of induction. Thus, some factors may be provided separately.
  • the medium (kit) may be accompanied by an instruction manual describing the method of use and preparation.
  • the medium for inducing differentiation into primitive endoderm can further contain other components necessary for the culture of naive type pluripotent stem cells.
  • PSC Human primed pluripotent stem cell
  • H9 ES embryonic stem cell
  • H1 ES cells AdiPS cells
  • F12 / KSR Dulbecco's modified Eagle medium [DMEM / F12; Nacalai Tesque, Cat .08460-95], 20% [v / v] KSR
  • Nonessential amino acids [NEAA; Thermo Fisher Scientific, Cat. 11140-050]
  • 4 ng / ml recombinant human bFGF [bFGF] Oriental yeast Cat.
  • NIB 47079000 0.1 mM 2-mercaptoethanol [Sigma-Aldrich, Cat. M3148] was used and maintained on ⁇ -irradiated MEF.
  • Cells were collected every 5 to 7 days with Dissociation Buffer (DB; 0.025% Trypsin [Thermo Fisher Scientific, Cat. 15090-046], 1 mg / ml Collagenase IV [Thermo Fisher Scientific, Cat. 17104-019], 20% KSR, 1 mM CaCl 2. Using 2 ), it was peeled off and passaged like a small clamp.
  • DB Dissociation Buffer
  • Human naive pluripotent stem cell line (H9 ES cells, H1 ES cells, Adi PS cells derived) is t2iLGo (Ndiff 227 [Takara Bio, Cat. Y40002], 1 ⁇ M PD0325901 [PD03; Tocris, Cat. 4192], 1 ⁇ M CHIR99021 [CH; Sigma-Aldrich, Cat. SML1046], 10 ng / ml Recombinant human LIF [hLIF; Peprotech, Cat. 300-05], 3 ⁇ M Go6983 [Go; Tocris, Cat. 2285]) were used to maintain on MEF. Cells were detached and passaged every 3 to 5 days using Accutase (Sigma-Aldrich, Cat. A6964).
  • the naive H9 PSC was established by a method using an HDAC inhibitor (Guo, G. et al. (2017). Development 144 (15): 2748-2763.).
  • EOS plasmid was introduced into primed H9 PSC by electroporation (primed H9 EOS).
  • a gene that is a drug resistance marker (puromycin resistance) is incorporated into the plasmid, and after introduction into cells, the cells into which the plasmid has been introduced by drug selection using Puromycin Dihydrochloride (Thermo Fisher Scientific, Cat. A1113802) was selected.
  • the primed H9 EOS is detached with trypsin / EDTA (Nacalai Tesque, Cat.
  • naive H9 was established using 5i LFA conditions (Theunissen et al., Cell Stem Cell. 2016 Oct 6; 19 (4): 502-515.). Primed H9 was detached with trypsin / EDTA into single cells, and 1 ⁇ 10 5 cells / cm 2 of cells were seeded onto MEFs in F12 / KSR medium supplemented with 10 ⁇ M Y-27632.
  • H1 PSC and AdiPS were established by a method using overexpression of NANOG and KLF2 (Takashima et al., Cell 158: 1254-1269, 2014).
  • a plasmid capable of inducing overexpression by DOX was electroporated and introduced into H1 and AdiPS (H1 NK2, AdiPS NK2).
  • a gene (a neomycin resistance) that is a drug resistance marker is incorporated into the plasmid, and after introduction into cells, selection of cells into which a plasmid has been introduced is carried out by drug selection using Geneticin (Thermo Fisher Scientific, Cat. 10131035) did.
  • Primed H1 NK2 and AdiPS NK2 were detached into single cells with trypsin / EDTA, and 1 ⁇ 10 5 cells / cm 2 of cells were added with 10 ⁇ M Y-27632 (Wako, Cat. 034-24024) F12 / It was seeded on MEF with KSR medium. The next day (day 1), 1 ⁇ g / ml doxycycline hyclate (Dox; Sigma-Aldrich, Cat. D9891) was added. Switch from Day 2 to 2iL (1 ⁇ M PD03, 1 ⁇ M CH, LIF) + Dox medium and culture for about 1 week. Then, it was established by switching to t2iLGo and maintaining.
  • naive PSC cultured on primitive endoderm-derived MEF are detached by Accutase and recovered, it is seeded on a gelatin-coated dish, and t2iLGo supplemented with 10 ⁇ M Y-27632 (ROCK inhibitor) at 37 ° C., 1 to 2 Incubate for time to remove MEF. Then resuspend in each induction medium and start induction simultaneously with seeding.
  • ROCK inhibitor 10 ⁇ M Y-27632
  • Ndiff 227 medium 25 ng / ml FGF4, 1 ⁇ g / ml heparin sodium, 10-200 ng / ml recombinant human BMP-4 (BMP-4; R & D, Cat. 314-BP), 10 ng / ml recombinant human PDGF-AA (PDGF-AA, Peprotech, Cat. 100-13A), 10 ng / ml recombinant human IL-6 (IL-6; Oriental Yeast, Cat.
  • BV421-anti-CD57 antibody (BD, Cat. 563896) was added in each combination and incubated on ice for 30 minutes. After washing, Streptavidin-APC (Biolegend, Cat. 405207), Streptavidin-PE (eBioscience, Cat. 12-4317-87), Streptavidin-BV421 (Biolegend, Cat. 405226) were added and incubated on ice for 20 minutes.
  • BD LSR Fortessa (BD) was used for FACS analysis, and FACS Aria II (BD) was used for sorting. Also, Flow Jo V10.2 software was used for data analysis.
  • SuperScript IV Thermo Fisher Scientific, Cat. 18090050
  • For real-time PCR use TaqMan Fast Universal Master Mix (Thermo Fisher Scientific, Cat. 4364103) and TaqMan probe, or PowerUP Sybr Green Master Mix (Thermo Fisher Scientific, Cat. A25743), and for PCR amplification QuantStudio 3 ( Thermo Fisher Scientific) was used. Analysis after Real-time RT-PCR reaction was performed using QuantStudio Design & Analysis Software v 1.4.1.
  • the cells were fixed with 4% paraformaldehyde (Nacalai Tesque, Cat. 09154-85) for 10 minutes at room temperature, and then permeabilized with PBS + 0.5% Triton X-100 for 1 hour at room temperature. The cells were blocked for 2 hours with PBS + 1% BSA + 0.05% Tween-20 (PBS-BT). Primary antibodies were added after dilution in PBS-BT and incubated for 2 hours at room temperature. After washing, the secondary antibody was diluted 1: 2000 in PBS-BT and incubated for 2 hours at room temperature. Nuclei were stained using DAPI (Sigma- Aldrich, Cat. D 9542).
  • PDGFRA-positive cells were recovered by FACS sorting from cells co-cultured with primitive endoderm cells and primed PSC GATA6 over-expressing or compound-induced cells.
  • the recovered cells were replated at a density of 3 ⁇ 10 5 cells / cm 2 on an iMatrix 511-coated slide glass.
  • primed PSC was exfoliated with DB (cell dissociation solution mixed with collagenase and trypsin) in a small clamp manner, and seeded on the cells replated on the slide.
  • the cells were cultured in primed ES cell culture medium (AK03, mTeSR1, F12 / KSR, etc.) alone or in a culture medium obtained by adding matrigel (5%) to primed ES cell culture medium.
  • Human naive PSC and primed PSC-derived PDGFRA-positive cells are different populations to generate human naive PSC, human primed ES cells (H9-primed cells) and human iPS cells (AdiPS-primed cells).
  • Human primed pluripotent stem cells (H9-EOS cells, AiPS-EOS cells) into which EOS vector had been introduced were treated with HDAC inhibitor, human naive PSC was induced and maintained in t2iLGo medium, and reset cells were established ( H9-naive cells, AiPS-naive cells).
  • GATA6, GATA4 and SOX17 When GATA6, GATA4 and SOX17 are overexpressed in mouse ES cells, they can be induced to primitive endoderm (PrE), and XEN cells can be established. Overexpression of GATA6, GATA4 and SOX17 in mouse ES cells is known to induce mouse PrE. Therefore, plasmids expressing GATA6, GATA4 or SOX17 were introduced into H9-naive and H9-primed cell lines under DOX induction (FIG. 1A). When DOX was added to H9-naive and differentiated in serum, naive dome-like colonies became flat and differentiated in any overexpression (FIG. 1B).
  • GATA4, GATA6 and SOX17 which are markers of PrE from human naive type, are expressed from day 2 and rise during day 4 in the cell line overexpressing GATA 6 (FIG. 1C).
  • Overexpression of GATA6 also induced expression of GATA4, 6, SOX17 (FIG. 1C, lower).
  • Overexpression of GATA4 was also found to induce gene expression, although not as much as GATA6.
  • cells overexpressing SOX17 could not express GATA4, GATA6, SOX17 (Endo) in the naive type. Even in the Primed type, expression was not able to be induced as much as GATA6 was overexpressed with only slight induction of the gene.
  • PrE is PDGFRA positive. It is also known that cells differentiated from mouse ES cells to PrE express PDGFRA. It is reported that PDGFRA is expressed in PrE of human embryo in analysis using single cell RNA sequence (Petropoulos, S. et al. (2016). Cell 165 (4): 1012-1026. And Blakeley, P. et al. (2015). Development 142 (18): 3151-3165.). When the expression of PDGFRA was confirmed by qPCR in the cells induced there, it was found that expression of PDGFRA is increased when GATA4, 6 is expressed similarly to the naive type and prime type (FIG. 1D). Therefore, expression of PDGFRA was confirmed by flow cytometry (FIG.
  • H9-naive-GATA6 PDGFRA-positive cells expressed PrA markers GATA3, 4, SOX17, HNF4A, FOXA2, COL4A1, while being pluripotent
  • the expression of sex markers OCT3 / 4 and NANOG decreased.
  • GATA6 and HNF4A were also induced from H9-naive-GATA4, but the PrE marker could not be induced as much as GATA6 (FIG. 1F).
  • Human naive PSC-derived PDGFRA-positive cells were induced using a non-serum medium, SFO3 medium or N2B27 medium, in order to clearly see differentiation signals equivalent to PrE.
  • GATA6 was overexpressed and induced by adding FGF4 in H9-naive-GATA6, about 30% of cells became PDGFRA positive in Day 1, and 80% of cells were PDGFRA positive in Day 3 (FIG. 2A) .
  • PDGFRA-positive cells were sorted, and their expression was confirmed.
  • PrE-related genes such as GATA4, SOX17, FOXA2, HNF4A, COL4A1, and SPARC were almost comparable under serum condition (GMEM) and non-serum condition (SFO3) (Figure 2B).
  • GMEM serum condition
  • SFO3 non-serum condition
  • comprehensive analysis using RNA sequences was performed.
  • H9-naive pluripotent stem cells and primed pluripotent stem cells were different in PC1, and PDGFRA-positive cells (Day 1, Day 3) induced by overexpressing GATA 6 were Similar to the naive and primed undifferentiated state, PC1 was different and PC2 was changed in the same direction (FIG. 2D). That is, it is suggested that they are different cell populations. Since it was suggested that the cells derived from H9-primed are mesodermal cells from FIG. 1G, when the expression of mesodermal genes was observed, in D1, the gene related to the early primitive streak was It is speculated to be expressed and induced into mesodermal cells (FIG. 2E).
  • GATA6 Modifies the Signal As a result of overexpression of GATA6, the naive form differentiates into PrE, while the primed form induces different cells expressing mesodermal genes, so to investigate the direct role of GATA6 ChIP-seq was performed using H9-naive-GATA6 and H9-primed-GATA6. GATA6 was actually bound to genes considered important for PrE such as GATA6, GATA4, SOX17, HNF4A (Fig. 3A). At the same time, it was found to bind to PDGFRA. Furthermore, it was bound to the secretion factor or receptor called BMP2, BMP6, IL6ST, FRZB (FIG. 3B). These were also confirmed to bind in ChIP-qPCR.
  • BMP2, BMP6 and FRZB were indeed elevated in PDGFRA after induction (FIG. 3C).
  • LEFTY and IL6ST were expressed from PSC and continued to be expressed after induction of differentiation.
  • GATA6 protein activation was examined, and phosphorylation of SMAD1 / 5/8, phosphorylation of MAPK, phosphorylation of STAT3, and phosphorylation of SMAD2 were suppressed (FIG. 3D). From this, GATA6 induces the secretion of BMP and PDGFA simultaneously with the induction of PrE gene group, while the induction of FRZB may suppress the Wnt signal.
  • GATA6 + GATA4 + SOX17 + cells GATA6 overexpression (FIG. 4E).
  • PDGFRA-positive cells were also induced by the 7-factor-containing medium, and it was similarly found that they express PrE-related genes and can be induced by the other two strains.
  • RNA sequencing was performed and exhaustive analysis was performed, it was found that a gene related to PrE was induced as in GATA6 overexpressing cells.
  • naive PSC When the novel human PrE-specific surface marker naive PSC is cultured with bFGF + ACTIVIN (TGFB), it converts to the primed form in about 10 days. It was reported that the naive PSC expresses the surface antigen CD75 and the primed one expresses the surface CD57.
  • naive type to PrE was induced with chemical (the above 7 factors), PDGFRA positive cells gradually decreased the expression of the naive marker CD75 in PDGFRA positive cells and did not express the prime marker CD57 (Fig. 5A).
  • PDGFA-positive cells were induced by overexpressing GATA6 in primed form, PDGFRA-positive cells were CD57 + CD75- (FIG. 5A). From the above, naive derived PrE was PDGFRA + CD75 +/ ⁇ CD57 ⁇ and prime derived cells were successfully separated by surface antigen as PDGFRA + CD75 ⁇ CD57 +.
  • CD75 can not completely separate the naive pluripotent stem cells that are epiblasts and the PDGFRA-positive cells that are PrE. Since PDGFRA is not specific for PrE, we searched for surface antigens that were specifically expressed by PrE and not in epiblast and mesoderm. Specific surface antigens were searched on the condition that GATA6 did not bind directly in ChIP sequence, was expressed in PDGFRA-positive PrE in RNA sequence, not in primed form, and was expressed in a published paper. By the way, CECAM1 was identified. When RNA of naive and primed PDGFRA-positive cells was compared by qPCR, CEACAM1 was observed to be expressed only by naive-derived PrE (FIG.
  • the cells can be maintained and cultured for more than 10 passages in a medium containing the factor, and the maintained cells expressed genes related to visceral endoderm / yolk sac cells and genes for extraembryonic mesenchymal cells).
  • genes related to visceral endoderm / yolk sac cells and genes for extraembryonic mesenchymal cells When gene expression was confirmed by RNA sequencing, naive type derived PDGFRA positive PrE cells actually express the yolk sac marker, and from H9-naive type, VE / YE can be induced via PrE but induced from primed Can not.
  • PrE In human development where PrE induces primed PSC into mesoderm, there is PrE in the lower layer of bilaminar epiblast, and bilaminar epiblast forms a primitive streak and differentiates into mesodermal cells. At this time, PrE is considered to play an important role. It was co-cultured with PSC and observed whether the induced PrE cells exhibited such ability. After 24 hours PSC became T positive cells and after 48 hours T positive cells migrated towards PrE (FIG. 6B). This indicates that PrE induced primed PSCs into mesoderm and was able to replicate the process of gastrulation in the early developmental stages in vitro. From the above, naive-type-derived PDGRA-positive cells not only express similar genes as PrE, but also may have functionally the same ability as PrE.
  • BMP, FGF and GATA6 cooperate to induce PrE.
  • 1 factor was subtracted from each of the 7 factors and differentiation was induced with 6 factors (FIG. 7A).
  • each of PD03 (MEC inhibitor), LDN193189 (BMP inhibitor), JaK inhibitor (JaKi), Activin, CH (Wnt activator) was added to 6 factors (FIG. 7A).
  • FGF4 or BMP was removed, almost no PDGFRA + cells were expressed, and it was found that FGF and BMP are essential for PrE induction.
  • PDGFRA-positive cells decreased only slightly by 31.5% when ACTIVIN inhibitor was removed and 33.2% when Wnt signal inhibitor was removed, but conversely, when ACTIVIN and Wnt stimulation were performed, primitive endoderm The cells were found to disappear. From the above, it was found that activin and Wnt inhibit primitive endoderm differentiation (FIG. 7A, lower). Although no data is shown, PDGFRA, CEACAM1 and ANPEP positive cells can not be induced with one factor of FGF alone or BMP4 alone, whereas PDGFRA, CEACAM1 and ANPEP positive cells when induced with two factors (FGF, BMP4) was obtained 9.1%.
  • FGF4 When differentiation was induced by four factors (FGF4, BMP4, XAV939, A83-01), 22.3% of PDGFRA, CEACAM1 and ANPEP positive cells were obtained. From these results, it was suggested that FGF and BMP are essential for PrE induction, and in addition to these, it is preferable to use a TGF ⁇ inhibitor and a Wnt signal inhibitor.
  • IL-6 when IL-6 was removed, a decrease in PDGFRA-positive cells was observed to 33.2%, but when JAKi was added, the cells did not proliferate, and almost no cells were present in D3. Therefore, when a low concentration of 100 nM JAKi was added, PDGFRA positive cells almost disappeared (FIG. 7A lower).
  • GP130 was activated and GP130Y118F chimeric receptor activating STAT3 was introduced into naive PSC to induce PrE. It was found that expression of chimeric receptor from D0 reduces expression of PDGFRA positive cells, whereas expression from D2 effectively induces PDGFRA positive cells (FIG. 7B). This indicates that in humans, JAK-STAT signal is important for maintenance of naive pluripotent stem cells and at the same time plays an important role in PrE (FIG. 7B).
  • GATA6 was knocked down using shGATA6, and PDGFRA positive cells were induced using 7 factors. However, neither PDGFRA-positive cells nor CEACAM1-positive cells were induced, and GATA6 was found to be a key gene essential for PrE induction (FIG. 7C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de préparation d'endoderme primitif à partir de cellules souches pluripotentes in vitro qui comprend une étape dans laquelle des cellules souches pluripotentes naïves sont cultivées dans un milieu de culture comprenant au moins une substance choisie parmi la protéine morphogénétique osseuse (BMP) et le facteur de croissance des fibroblastes 4 (FGF4), et de préférence également le facteur de croissance dérivé des plaquettes (PDGF), l'interleukine-6 (IL-6), l'inhibiteur de TGFβ, l'inhibiteur de signal Wnt et l'acide rétinoïque, et la différenciation endodermique primitive est induite.
PCT/JP2018/041243 2017-11-07 2018-11-06 Procédé d'induction d'endoderme primitif à partir de cellules souches pluripotentes naïves WO2019093340A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019552818A JP7176764B2 (ja) 2017-11-07 2018-11-06 ナイーブ型多能性幹細胞からの原始内胚葉誘導方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017215115 2017-11-07
JP2017-215115 2017-11-07

Publications (1)

Publication Number Publication Date
WO2019093340A1 true WO2019093340A1 (fr) 2019-05-16

Family

ID=66438820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/041243 WO2019093340A1 (fr) 2017-11-07 2018-11-06 Procédé d'induction d'endoderme primitif à partir de cellules souches pluripotentes naïves

Country Status (2)

Country Link
JP (1) JP7176764B2 (fr)
WO (1) WO2019093340A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262531A1 (fr) * 2019-06-26 2020-12-30 国立研究開発法人理化学研究所 Inducteur de cellule souche d'endoderme primitif
WO2021102500A1 (fr) * 2019-11-26 2021-06-03 The University Of Western Australia Procédés de reprogrammation d'une cellule
WO2021107117A1 (fr) * 2019-11-28 2021-06-03 国立大学法人京都大学 Procédé de production d'une cellule hématopoïétique à partir d'une cellule souche pluripotente
WO2022050419A1 (fr) 2020-09-04 2022-03-10 Ｈｅａｒｔｓｅｅｄ株式会社 Agent améliorant la qualité des cellules ips, procédé de production de cellules ips, cellules ips, et composition pour la production de cellules ips
WO2022114188A1 (fr) * 2020-11-30 2022-06-02 国立大学法人京都大学 Modèle de blastocystis bilaminaris et procédé de production de celui-ci
WO2022138964A1 (fr) * 2020-12-25 2022-06-30 国立大学法人京都大学 Procédé de production de cellules souches pluripotentes humaines naïves à partir de cellules somatiques
WO2024048731A1 (fr) * 2022-08-31 2024-03-07 国立大学法人京都大学 Procédé de production de cellules souches pluripotentes naïves

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534065A (ja) * 2007-07-20 2010-11-04 セルアーティス アーベー ヒト胚盤胞幹細胞に、胚体内胚葉（ＤＥ‐ｈｅｐ）を介して由来する新規な肝細胞の集団

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534065A (ja) * 2007-07-20 2010-11-04 セルアーティス アーベー ヒト胚盤胞幹細胞に、胚体内胚葉（ＤＥ‐ｈｅｐ）を介して由来する新規な肝細胞の集団

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUKKER M. ET AL.: "Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells", NAT BIOTECHNOL, vol. 30, no. 6, 2013, pages 531 - 542, XP055083938, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672406/pdf/nihms469343.pdf> [retrieved on 20190117], DOI: doi:10.1038/nbt.2239 *
KANG M. ET AL.: "Lineage Establishment and Progression within the Inner Cell Mass of the Mouse Blastocyst Requires FGFR1 and FGFR2", DEVELOPMENTAL CELL, vol. 41, no. 5, 5 June 2017 (2017-06-05), pages 496 - 510, XP085056827, ISSN: 1534-5807, DOI: 10.1016/j.devcel.2017.05.003 *
TAKASHIMA YASUHIRO: "Induction of preimplantation extraembryonic tissue of human and analysis of early development of human, using initialization technique", 2015 PERFORMANCE REPORT, 6 January 2017 (2017-01-06), Retrieved from the Internet <URL:https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-15H06329> [retrieved on 20190128] *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262531A1 (fr) * 2019-06-26 2020-12-30 国立研究開発法人理化学研究所 Inducteur de cellule souche d'endoderme primitif
WO2021102500A1 (fr) * 2019-11-26 2021-06-03 The University Of Western Australia Procédés de reprogrammation d'une cellule
WO2021107117A1 (fr) * 2019-11-28 2021-06-03 国立大学法人京都大学 Procédé de production d'une cellule hématopoïétique à partir d'une cellule souche pluripotente
WO2022050419A1 (fr) 2020-09-04 2022-03-10 Ｈｅａｒｔｓｅｅｄ株式会社 Agent améliorant la qualité des cellules ips, procédé de production de cellules ips, cellules ips, et composition pour la production de cellules ips
WO2022114188A1 (fr) * 2020-11-30 2022-06-02 国立大学法人京都大学 Modèle de blastocystis bilaminaris et procédé de production de celui-ci
WO2022138964A1 (fr) * 2020-12-25 2022-06-30 国立大学法人京都大学 Procédé de production de cellules souches pluripotentes humaines naïves à partir de cellules somatiques
WO2024048731A1 (fr) * 2022-08-31 2024-03-07 国立大学法人京都大学 Procédé de production de cellules souches pluripotentes naïves

Also Published As

Publication number Publication date
JPWO2019093340A1 (ja) 2021-03-25
JP7176764B2 (ja) 2022-11-22

Similar Documents

Publication Publication Date Title
JP7282304B2 (ja) 新規ドーパミン産生神経前駆細胞の誘導方法
WO2019093340A1 (fr) Procédé d&#39;induction d&#39;endoderme primitif à partir de cellules souches pluripotentes naïves
JP7356658B2 (ja) ドーパミン産生神経前駆細胞の製造方法
JP7166631B2 (ja) 新規軟骨細胞誘導方法
US9796959B2 (en) Method for inducing astrocytes
US10557121B2 (en) Method for chondrogenic induction
WO2021106765A1 (fr) Procédé d&#39;induction de trophectoderme à partir de cellules souches pluripotentes naïves
US20210332329A1 (en) Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
JP2014506447A (ja) 多能性幹細胞から樹状細胞を製造する方法
JP6646311B2 (ja) 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
JP2020115771A (ja) 多能性幹細胞から軟骨組織を製造する方法
JP7072756B2 (ja) 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
WO2022114188A1 (fr) Modèle de blastocystis bilaminaris et procédé de production de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18876806

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019552818

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18876806

Country of ref document: EP

Kind code of ref document: A1